HRT: A Complete Evidence-Based Guide to Hormone Replacement Therapy

What Is Hormone Replacement Therapy?

Hormone replacement therapy, commonly called HRT or menopausal hormone therapy (MHT), involves supplementing the hormones your ovaries gradually stop producing as you approach and pass through menopause. The primary hormones involved are estrogen and progesterone, though testosterone is increasingly part of the conversation.

During perimenopause, which can begin in your early 40s, hormone levels start to fluctuate unpredictably. By the time you reach menopause (defined as 12 consecutive months without a period, at an average age of 51), estrogen production has dropped significantly. This decline drives the symptoms most women associate with menopause: hot flashes, night sweats, sleep disruption, vaginal dryness, mood changes, and brain fog (Santoro et al., 2015).

HRT works by restoring hormone levels to a range that alleviates these symptoms. It does not aim to replicate the hormone levels of your 20s. Rather, it provides enough hormonal support to protect your tissues, bones, and cardiovascular system during a vulnerable transition.

Types of HRT

Estrogen-Only Therapy (ET)

Estrogen-only HRT is prescribed for women who have had a hysterectomy. Without a uterus, there is no risk of endometrial cancer from unopposed estrogen, so progesterone is unnecessary. Estrogen-only therapy has the most favorable risk profile of all HRT types and was associated with a slight decrease in breast cancer risk in the Women’s Health Initiative (WHI) trial (WHI Steering Committee, 2006).

Combined Estrogen-Progesterone Therapy (EPT)

If you still have your uterus, you need progesterone (or a progestogen) alongside estrogen. Estrogen alone stimulates the uterine lining, which can lead to endometrial hyperplasia and cancer over time. Progesterone counteracts this effect. Combined therapy can be given cyclically (progesterone for 10 to 14 days per month, producing a withdrawal bleed) or continuously (daily progesterone with no bleed) (The NAMS 2017 Hormone Therapy Position Statement).

Delivery Methods

How you take HRT matters, sometimes as much as what you take. Here are the main options:

• Transdermal patches: Applied to the skin once or twice weekly. Patches bypass the liver entirely, which means they do not increase clotting risk. This is widely considered the safest delivery route for estrogen (Mohammed et al., 2015).
• Topical gels and creams: Applied daily to the skin. Like patches, these are transdermal and carry a lower clot risk than oral formulations.
• Oral pills: Taken daily. Convenient, but oral estrogen passes through the liver (first-pass metabolism), which increases production of clotting factors and certain inflammatory markers.
• Vaginal estrogen: Low-dose creams, rings, or tablets applied locally. These treat vaginal and urinary symptoms with minimal systemic absorption. Most guidelines consider vaginal estrogen safe even for women with contraindications to systemic HRT (The NAMS, 2020).
• Subcutaneous pellets: Small pellets inserted under the skin every 3 to 6 months. They provide steady hormone levels but are harder to adjust or remove if problems arise. Pellets are not FDA-approved and are typically compounded.
• Injections: Intramuscular injections of estrogen (estradiol valerate or cypionate) given every 1 to 2 weeks. Less commonly used for menopause; more common in transgender hormone therapy.

Progesterone Options

For the progesterone component, you have two broad categories:

• Micronized progesterone (Prometrium): Chemically identical to the progesterone your body makes. Generally better tolerated, with a more favorable effect on lipids, mood, and sleep. The KEEPS and E3N studies suggest micronized progesterone may carry less breast cancer risk than synthetic progestins (Fournier et al., 2008).
• Synthetic progestins (medroxyprogesterone acetate, norethindrone): These are not identical to your body’s progesterone. Medroxyprogesterone acetate (MPA), used in the WHI, has been linked to a higher breast cancer risk compared to micronized progesterone.
• Levonorgestrel IUD (Mirena): Increasingly used off-label to provide endometrial protection while delivering progesterone locally to the uterus, minimizing systemic side effects.

Bioidentical vs. Synthetic: What the Evidence Actually Shows

The term “bioidentical” refers to hormones that are chemically identical to those your body produces. Estradiol, estriol, progesterone, testosterone, and DHEA are all bioidentical hormones. Many FDA-approved products contain bioidentical hormones. The estradiol in your patch and the micronized progesterone in your Prometrium capsule are bioidentical.

The confusion arises because the term has been co-opted by compounding pharmacies and some practitioners to market custom-mixed hormone preparations. These compounded “bioidentical hormone replacement therapy” (BHRT) products are not FDA-regulated, meaning they have not undergone the same rigorous testing for safety, efficacy, potency, and purity (ACOG Committee Opinion, 2019).

There are legitimate reasons to use compounded hormones. Some women need doses or combinations not commercially available, or they have allergies to inactive ingredients in standard products. But the marketing claim that compounded BHRT is inherently safer than FDA-approved HRT is not supported by evidence. Both the Endocrine Society and ACOG recommend FDA-approved bioidentical hormones as first-line therapy when possible.

Salivary hormone testing, often promoted by BHRT practitioners, is not reliable for monitoring or dosing HRT. Serum (blood) testing is the standard (Endocrine Society, 2016).

Who Needs HRT?

HRT is not a blanket recommendation for every woman entering menopause. But for several groups, the evidence strongly favors treatment:

• Women with moderate to severe vasomotor symptoms: If hot flashes and night sweats are disrupting your sleep, work, or quality of life, HRT is the most effective treatment available. It reduces hot flash frequency by roughly 75% (Maclennan et al., 2004).
• Premature ovarian insufficiency (POI): Women who stop menstruating before age 40. Without hormone replacement, these women face elevated risks of osteoporosis, cardiovascular disease, cognitive decline, and early death. HRT is considered medically necessary, not optional, for this group (Webber et al., 2016).
• Surgical menopause: Women who have had their ovaries removed experience an abrupt, complete loss of hormones. The symptom burden is often severe, and early HRT is strongly recommended.
• Genitourinary syndrome of menopause (GSM): Vaginal dryness, painful intercourse, recurrent UTIs, and urinary urgency. Low-dose vaginal estrogen is first-line treatment and is effective for the vast majority of women.
• Women at high risk of osteoporosis: HRT is the only menopause treatment that both relieves symptoms and protects bone density. It reduces hip fractures by 34% according to WHI data.

Benefits of HRT

Symptom Relief

This is the primary reason most women start HRT, and it is remarkably effective. Hot flashes, night sweats, sleep disruption, vaginal dryness, and mood instability all respond well to appropriate hormone therapy. For many women, the improvement in quality of life is dramatic.

Bone Protection

Estrogen is critical for maintaining bone density. After menopause, women can lose up to 20% of their bone density within 5 to 7 years. HRT halts this loss and reduces fracture risk at the hip, spine, and other sites. This benefit is maintained for as long as therapy continues (Rossouw et al., 2002; WHI).

Cardiovascular Protection: The Timing Hypothesis

This is where the story gets nuanced. The WHI initially suggested HRT increased heart disease risk. But subsequent reanalysis revealed a critical detail: age and timing matter enormously.

Women who started HRT within 10 years of menopause or before age 60 showed a trend toward reduced cardiovascular events. Women who started HRT more than 10 to 20 years after menopause, when atherosclerosis may already be established, showed increased risk. This is known as the “timing hypothesis” or “window of opportunity,” and it has been supported by multiple subsequent analyses and the ELITE trial (Hodis et al., 2016).

Transdermal estrogen, which avoids liver first-pass effects, appears to have the most favorable cardiovascular profile. The Danish Osteoporosis Prevention Study (DOPS), which followed women for over 16 years, found that those randomized to HRT early in menopause had significantly reduced risk of heart failure, heart attack, and death without any increased cancer risk (Schierbeck et al., 2012).

Cognitive Benefits

Observational data suggest that HRT started early in menopause may protect against cognitive decline and possibly reduce Alzheimer’s risk. The WHIMS (WHI Memory Study) found increased dementia risk, but that study enrolled women aged 65 to 79, well past the proposed window of benefit. Research on early initiation, including the KEEPS-Cog and ELITE trials, has been more encouraging, though definitive evidence is still emerging (Henderson & Brinton, 2021).

Other Benefits

HRT has been associated with reduced risk of type 2 diabetes, improved joint health, better skin elasticity and wound healing, and reduced risk of colon cancer (in the WHI combined therapy arm). Some women also report improvements in energy, libido, and overall well-being.

Risks and the WHI Controversy

The Study That Changed Everything

In 2002, the WHI estrogen-plus-progestin trial was halted early after finding increased rates of breast cancer, heart disease, stroke, and blood clots. Headlines were alarming. Millions of women abruptly stopped HRT, and prescriptions dropped by over 50% worldwide.

But the story was more complicated than the headlines suggested. The average age of WHI participants was 63, more than a decade past menopause. The formulation used was oral conjugated equine estrogen (Premarin) plus medroxyprogesterone acetate (Provera), a specific combination that may not reflect modern HRT practice. The absolute risk increases were small: roughly 8 additional breast cancers per 10,000 women per year (Writing Group for the WHI, 2002).

Breast Cancer Risk: The Nuances

The breast cancer question is the most common concern women raise. Here is what the evidence shows:

• Estrogen-only therapy (for women without a uterus) was associated with a decreased risk of breast cancer in the WHI, even after 20 years of follow-up (Chlebowski et al., 2020).
• Combined estrogen-progestogen therapy was associated with a small increased risk, appearing after approximately 3 to 5 years of use.
• The type of progestogen matters. Micronized progesterone and dydrogesterone appear to carry less risk than synthetic progestins like MPA (Fournier et al., 2008).
• To put the risk in perspective, the increase is similar to the breast cancer risk associated with drinking one to two glasses of wine per day, being obese, or being sedentary.

Blood Clot Risk

Oral estrogen increases the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) because of its effect on liver clotting factor production. Transdermal estrogen does not carry this increased risk, which is why most menopause specialists now prefer patches, gels, or sprays, especially for women with additional clot risk factors (obesity, smoking, thrombophilia) (Mohammed et al., 2015).

Stroke Risk

There is a small increased risk of ischemic stroke with oral HRT, particularly at higher doses. Again, transdermal delivery and lower doses appear to mitigate this risk. For women under 60, the absolute risk is very low.

Testosterone for Women

Testosterone is not just a “male hormone.” Women produce testosterone in their ovaries and adrenal glands, and levels decline with age. After menopause, testosterone levels are roughly half of what they were at age 20.

The most well-supported indication for testosterone therapy in women is hypoactive sexual desire disorder (HSDD), basically low libido that causes distress. A 2019 global consensus statement concluded that testosterone at physiological doses can improve sexual desire, arousal, orgasm, and satisfaction in postmenopausal women (Davis et al., 2019).

Some practitioners also prescribe testosterone for energy, mood, cognitive sharpness, and muscle maintenance, though the evidence for these indications is less established. No testosterone product is currently FDA-approved for women, so prescriptions are typically compounded or involve off-label use of low-dose male formulations.

Side effects at appropriate doses are uncommon but can include acne, facial hair growth, and voice deepening if levels go too high. Monitoring with blood tests is important to keep levels within the physiological female range.

DHEA (dehydroepiandrosterone) is another androgen precursor sometimes prescribed alongside or instead of testosterone. An intravaginal DHEA product (Intrarosa/prasterone) is FDA-approved for treating painful intercourse due to menopause. Oral DHEA supplements are available over the counter, though their efficacy and safety for menopause symptoms are not well established in clinical trials.

Starting HRT: What to Expect

If you and your provider decide HRT is right for you, here is a realistic timeline of what to expect. Most women notice improvement in vasomotor symptoms (hot flashes, night sweats) within the first 2 to 4 weeks, though full benefit may take up to 3 months. Vaginal dryness and urinary symptoms improve more slowly, sometimes taking 3 to 6 months of consistent local estrogen use.

Sleep quality often improves early, partly because night sweats diminish. Mood stabilization can take several weeks. Some women experience breast tenderness, bloating, or irregular bleeding during the first 1 to 3 months as the body adjusts. These side effects typically resolve on their own. If they persist, your provider may adjust the dose or formulation.

It is common to need dose adjustments in the first 6 months. This is normal and not a sign that something is wrong. Your provider should schedule a follow-up visit within 2 to 3 months of starting therapy to review symptom response and address any concerns.

Monitoring and Lab Work

Once you start HRT, regular follow-up is important. Here is what most menopause specialists will monitor:

• Symptom check: Are your hot flashes, sleep, mood, and vaginal symptoms improving? Symptom response is the primary guide to dosing.
• Estradiol levels: Useful for ensuring adequate absorption, particularly with transdermal delivery. Target ranges vary but typically aim for 40 to 100 pg/mL for symptom relief.
• FSH: Less useful for dose adjustment once on HRT, but helpful in confirming menopause status before starting therapy.
• Testosterone levels: If supplementing testosterone, free and total testosterone should be checked to avoid supraphysiological levels.
• Lipid panel and metabolic markers: HRT can affect lipids (generally favorably with transdermal estrogen).
• Mammograms and breast exams: Continue routine screening. HRT, especially combined therapy, can increase breast density, which may require additional imaging.
• Endometrial monitoring: Any unexpected bleeding on HRT should be evaluated with ultrasound and possibly biopsy.

How Long Should You Stay on HRT?

The old advice of “lowest dose for the shortest time” was born out of post-WHI anxiety and is increasingly being questioned. Here is a more contemporary perspective:

There is no arbitrary time limit on HRT. The decision to continue should be individualized and revisited annually. For women who started HRT for vasomotor symptoms, many find that symptoms persist for 7 to 10 years or longer. Stopping HRT just because five years have passed makes little sense if symptoms return.

For women with premature ovarian insufficiency, HRT should continue at minimum until the average age of natural menopause (51) and often beyond. For bone protection, HRT benefits last only as long as treatment continues. The 2022 Menopause Society position statement supports continued use when benefits outweigh risks for the individual patient (The Menopause Society, 2022).

Coming Off HRT

If you and your provider decide it is time to stop HRT, gradual tapering is generally preferred over abrupt discontinuation. A common approach is to reduce the dose by one step every 2 to 3 months. This minimizes the likelihood of symptom rebound.

Be aware that some women find symptoms return when they try to stop, even after years of therapy. This is not a sign of dependence. It is a sign that your body still has a significant hormone deficit. In these cases, continuing low-dose therapy or switching to vaginal estrogen alone for GSM symptoms is a reasonable option.

Finding a Menopause Specialist

One of the biggest barriers to good HRT care is provider knowledge. Studies show that many primary care physicians and even OB-GYNs receive minimal training in menopause management. A 2013 survey found that only 20% of OB-GYN residency programs had a formal menopause curriculum (Christianson et al., 2013).

If your provider is uncomfortable prescribing HRT or relies on outdated WHI-era fears, seek a specialist. Look for:

• NAMS-certified menopause practitioners (NCMP): The North American Menopause Society certifies providers who have passed a competency exam. Search their directory at menopause.org.
• Reproductive endocrinologists with menopause expertise.
• Endocrinologists who specialize in female hormones.
• Telemedicine menopause clinics have expanded access significantly in recent years. Several platforms now specialize in evidence-based menopause care.

Frequently Asked Questions

Is HRT safe if I have a family history of breast cancer?

A family history of breast cancer is not an automatic contraindication. The decision depends on specifics: which relative, at what age, whether genetic testing (BRCA1/2) has been done, and how severe your symptoms are. Estrogen-only therapy (if applicable) does not appear to increase breast cancer risk. Discuss your individual risk with a breast oncologist or menopause specialist.

Will HRT cause weight gain?

No. Menopause itself is associated with changes in body composition (more abdominal fat, less muscle mass), but randomized trials show HRT does not cause weight gain and may actually help prevent the shift to central adiposity (Davis et al., 2012).

Can I take HRT if I have migraines?

Migraines with aura are a risk factor for stroke, and oral estrogen may increase this risk. Transdermal estrogen at a steady dose (avoiding fluctuations) is generally considered safer for women with migraines. Your provider should assess your specific migraine type and other risk factors.

What about “natural” alternatives to HRT?

Phytoestrogens (soy isoflavones), black cohosh, and other supplements have been studied. The evidence for most is weak to modest. Some women get mild relief, but nothing matches the efficacy of HRT for moderate to severe symptoms. CBT and clinical hypnosis have some evidence for hot flash management. If you cannot or choose not to take HRT, non-hormonal prescription options like fezolinetant (Veozah) and SSRIs/SNRIs can help (Johnson et al., 2023).

The Bottom Line

HRT has been through decades of controversy, but the science has matured considerably. For the right woman, at the right time, with the right formulation, it remains the gold standard for menopause symptom management and offers meaningful benefits for bone, heart, and possibly brain health.

The key is individualized care from a knowledgeable provider who understands the nuances. Do not let fear from outdated headlines keep you from a treatment that could significantly improve your quality of life during menopause and beyond.

References

1. Santoro N, Epperson CN, Mathews SB. Menopausal Symptoms and Their Management. Endocrinol Metab Clin North Am. 2015;44(3):497-515. PubMed
2. Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2006;295(14):1647-1657. PubMed
3. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753. PubMed
4. Mohammed K, Abu Dabrh AM, Benkhadra K, et al. Oral vs Transdermal Estrogen Therapy and Vascular Events. J Clin Endocrinol Metab. 2015;100(11):4012-4020. PubMed
5. The North American Menopause Society. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer. Menopause. 2020;27(12):1397-1402. PubMed
6. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies. Breast Cancer Res Treat. 2008;107(1):103-111. PubMed
7. Endocrine Society. Testosterone Therapy in Women: A Clinical Practice Guideline. J Clin Endocrinol Metab. 2016. PubMed
8. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;(4):CD002978. PubMed
9. Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926-937. PubMed
10. Hodis HN, Mack WJ, Henderson VW, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol (ELITE). N Engl J Med. 2016;374(13):1221-1231. PubMed
11. Henderson VW, Brinton RD. Menopause and Mitochondria: Windows into Estrogen Effects on Alzheimer’s Disease Risk and Therapy. Prog Brain Res. 2021;182:77-96. PubMed
12. Writing Group for the Women’s Health Initiative. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. JAMA. 2002;288(3):321-333. PubMed
13. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the WHI Randomized Clinical Trials. JAMA. 2020;324(4):369-380. PubMed
14. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PubMed
15. Christianson MS, Ducie JA, Engber K, et al. Menopause education: needs assessment of American obstetrics and gynecology residents. Menopause. 2013;20(11):1120-1125. PubMed
16. Davis SR, Castelo-Branco C, Chedraui P, et al. Understanding weight gain at menopause. Climacteric. 2012;15(5):419-429. PubMed
17. Johnson KA, Martin N, Nappi RE, et al. Efficacy and Safety of Fezolinetant for Moderate to Severe Vasomotor Symptoms. J Clin Endocrinol Metab. 2023. PubMed
18. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PubMed
19. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. PubMed

Related Reading

• Shockwave Therapy: A Complete Evidence-Based Guide
• Peptide Therapy: What the Evidence Says
• Red Light Therapy: Benefits, Evidence, and How to Use It
• Functional Medicine: What It Is and What to Expect